Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Yichang HEC Changjiang Pharma (1558 HK)
Watchlist
75
Analysis
Health Care
•
Hong Kong
YiChang HEC ChangJiang Pharmaceutical Co Ltd develops a variety of drugs. The Company develops and sells drugs for anti-virus, metabolic diseases, cardiovascular, and more.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Yichang HEC Changjiang Pharma
•
19 May 2024 07:05
Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid
Maybe this gets up. Maybe this is worth HK$19.30/share. Too many maybes. If in, I'd vote this transaction down. If not in, I'd be looking elsewhere.
David Blennerhassett
Follow
442 Views
Share
bearish
•
Yichang HEC Changjiang Pharma
•
16 May 2024 08:55
HEC CJ Pharma (1558.HK)'s Merger Deal with Sunshine Lake Pharma - Almost No Investment Value
Sunshine Lake Pharma plans to privatize and merge with CJ Pharma.However, with an outdated pipeline, the new entity's valuation performance will...
Xinyao (Criss) Wang
Follow
286 Views
Share
bullish
•
Yichang HEC Changjiang Pharma
•
11 May 2024 23:48
HEC CJ Pharma (1558 HK): Pre-Conditional Share Exchange Offer from Largest Shareholder
There is scrip valuation uncertainty as the offeror is unlisted, and its valuation hinges on pipeline products. Nevertheless, the deal should get...
Arun George
Follow
462 Views
Share
bullish
•
Yichang HEC Changjiang Pharma
•
04 Jan 2024 09:30
HEC Pharma (1558 HK): Strong Performance to Continue as Flu Activity Is On Rise In China
HEC Pharma should benefit from the upsurge in respiratory illness in China. With a forward P/E of 4.8x and 14% YoY EPS growth expectation for 2024,...
Tina Banerjee
Follow
640 Views
Share
bullish
•
Yichang HEC Changjiang Pharma
•
02 Oct 2023 21:57
HEC Pharma (1558 HK): Robust 1H23 Performance on Flu Outbreak in China
HEC Pharma reports impressive revenue growth of 148% YoY in 1H23, driven by strong sales of Kewei for influenza treatment. The company obtained...
Tina Banerjee
Follow
442 Views
Share
1
2
3
4
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x